ISSN:0378-584X    

DOI:10.1159/000217323

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217324

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217422

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

ISSN:0378-584X    

DOI:10.1159/000217423

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Only 10% to 20% of the patients with a primary or secondary liver tumor are candidates for partial liver resection. For the remaining majority of patients only palliative methods are applicable: Systemic and regional chemotherapy, chemoembolisation, endoscopic and percutaneous drainage, and methods still in experimental evaluation. However the number of these many different methods indicates that ‘The one method’ still has not yet been determined. Until now no benefit of one therapy compared to another or to the natural course of the disease has been demonstrated. Only trends can be concluded from the different studies. Therefore we think that the palliative therapy of liver tumors should be restricted to centers which attend prospective, randomized studies to solve this prob

ISSN:0378-584X    

DOI:10.1159/000217325

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Fifteen AML patients with first or subsequent relapse and three patients with primary refractory disease were treated with a combination of idarubicin (8 mg/m2, three doses), cytosine arabinoside (100 mg/m2, six doses) and etoposide (100 mg/m2, five doses) for induction of a subsequent remission. Six patients (33%) achieved a subsequent remission, two patients (11%) a partial remission, eight patients (45%) were treatment failures and two patients 11 % died during induction therapy due to infectious complications. One of the patients died in CR during autologous bone marrow transplantation, whereas the remaining five complete responders suffered from a subsequent relapse (three of five after bone marrow transplantation, two of five after further consolidation therapy) with a median remission duration of 254 days. Major non-hematological toxicity was due to infectious complications, while no severe cardiac side effects were found despite the fact that most patients had been heavily pretreated with anthracyclines. Hematotoxicity was profound with grade IV (WHO criteria) toxicity in all cases under study with a median duration of critical granulocytopenia of 22 days and of critical thrombocytopenia of 20 days during the first induction course.

ISSN:0378-584X    

DOI:10.1159/000217326

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Twenty-one patients with primary gastrointestinal sarcomas underwent surgery at the University Clinics of Hamburg from 1970 to 1990. Main symptoms were gastrointestinal bleeding and abdominal pain. All but two tumors were classified as leiomyo-sarcomas. Seven sarcomas were located in the stomach, two in the duodenum, eight in the small and four in the large intestine or rectum. Seven patients presented lymph node and/or distant metastases. Complete resection was possible in 71% of the cases. Six patients received chemotherapy for metastatic disease. Five of the respective tumors showed progression under therapy, while the sixth patient had a complete remission of 55 months by the end of the study period. The mean survival time was 57 months and the five-year survival rate 46%. In contrast to literature data, tumor grade was not the most important prognostic factor in this series, but rather regional lymph node metastasis and local recurrence, predicting poor outcome.

ISSN:0378-584X    

DOI:10.1159/000217327

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Grundlagen: Bei der Therapie des metastasierenden Mammakarzinoms korreliert die Rate der Remissionen (CR & PR) nicht notwendigerweise mit dem Benefit für die Patienten. Diese Rate ist abhängig von Variablen des Tumors wie Polyklonalität, Resistenz und Wachstumskinetik. Ein Modell, welches diese Variablen berücksichtigt, sagt voraus, daß eine schlechte Prognose auf Patienten mit früher Progression begrenzt ist aber eine gute Prognose nicht auf Patienten mit früher CR & PR. Patienten und Methoden: Um die vorhergesagten Ergebnisse zu bestätigen, wurden 134 Patienten mit zwei Zyklen des FEC Regimes behandelt. Die Überlebenszeit wurde bei Patienten mit CR & PR und bei Patienten mit SD bestimmt (Studie A). Um vergleichbare Ansprechraten nach FEC und einer gut tolerierten Therapie zu zeigen, beurteilten wir das Ansprechen bei 46 Patienten nach jedem der drei verabreichten Zyklen des 3M-Regimes (Studie B).Ergebnisse: Patienten mit CR & PR (n = 38) oder SD (n = 49) überlebten unabhän-gig von der Folgetherapie zusätzliche 13,2 bzw. 12,8 Monate. Patienten mit PD(n = 23) überlebten lediglich 2,9 Monate (p < 0.0001). Nach sechswöchiger Therapie wurde ein vergleichbares Ansprechen nach FEC (28% CR & PR, 37% SD, Studie A) und nach 3M (24% CR & PR, 57% SD, Studie B) beobachtet. Schlußfolgerung: Die Relevanz einer SD sollte bei metastasierendem Mammakarzinom nicht unterschätzt werden. Eine symptomfreie und stabile Erkrankungsphase könnte bei diesen Patienten ein relevantes T

ISSN:0378-584X    

DOI:10.1159/000217328

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Clinical studies analyzing sequential serum levels suggest pathophysiological involvement of Tumor-Necrosis-Factor-alpha (TNFa) in acute graft-versus-host disease (aGvHD) and endothelial complications following allogeneic bone marrow transplantation (BMT). For further investigation of the role of TNFa in aGvHD a neutralizing rb-anti-ms-TNFalpha antibody or pentoxifylline (PTX) as an inhibitor of TNFa-transcription were injected in lethally irradiated mice before or following transplantation of semi- or fully allogeneic bone marrow and various T-cell doses. Prophylactic application of anti-TNFa either prior to irradiation and BMT (p < .05) or at weekly intervals from d7 until d35 (p < .Ol) significantly reduced aGvHD-related mortality and cachexia, when low doses of semiallogeneic T cells were used for induction of aGvHD. Under these conditions, only a marginal protective effect could be obtained by long term application of PTX. In addition, aGvHD induced by high doses of T cells or by transfer of fully allogeneic T lymphocytes could not be prevented by anti-TNFa. These results further indicate that neutralization of TNFa might be helpful as an additive strategy for prevention of aGvHD especially in HLA-identical BMT.

ISSN:0378-584X    

DOI:10.1159/000217329

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger

摘要:

Cellular DNA content abnormalities as well as in vitro bromodeoxyuridine (BrdUrd) labeling was assessed simultaneously by flow cytometry in 62 primary squamous cell carcinomas of the oral cavity. DNA aneuploidy proved to be a striking indicator of malignancy progression. The proportion of aneuploid tumors increased with stage (Tl: 17%; T2: 74%; T3: 90%) as well as with histologic grade (Gl: 25%; G2: 70%; G3: 91%). Only one of 24 patients with metastatic disease had a diploid primary tumor. BrdUrd/DNA flow cytometry of aneuploid tumors allowed selective assessment of proliferation of tumor cell populations alone by excluding non-malignant diploid cells. Prognostic implications of the aneuploid BrdUrd labeling indices (5.2% ± 3.8) could not be confirmed in spite of the remarkable individual differences (.6%–18.1%). Cellular proliferation in oral cancer appears to represent a parameter of individual tumor growth rather than a marker of malignancy progressi

ISSN:0378-584X    

DOI:10.1159/000217330

出版商:S. Karger GmbH    

年代:1992

数据来源: Karger